Prophylactic administration (on day 7 before EAE induction) of MOG-conjugated PLGA nanoparticles demonstrated the most promising results in this mouse model of MS, significantly reducing disease severity and brain inflammation and promoting a regulatory immune response. Here, MOG is linked to myeloid sarcoma.